Skip to main content
Clinical Trials/NL-OMON51476
NL-OMON51476
Recruiting
N/A

changed right heart volumes and function following diuretic withdrawal in pulmonary hypertension - Diuretic effect on the right heart

Amsterdam UMC0 sites17 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Amsterdam UMC
Enrollment
17
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • \- Diagnosed with idiopathic PAH, hereditary PAH, drug\- and toxins induced PAH
  • according to ESC/ERS pulmonary hypertension guidelines
  • \- Minimal dosage of 40mg furosemide or 1mg bumetanide a day
  • \- NYHA classification II
  • \- Age \>\=18 and \<\=80 years
  • \- Able to understand and willing to sign the Informed Consent Form

Exclusion Criteria

  • \- Pregnant subjects
  • \- Inability to provide informed consent
  • \- Change in PAH specific therapy within 3 months before diuretic withdrawal
  • \- Change in (dose of) any other medication
  • \- Hospitalized for acute decompensation within one year before diuretic
  • \- One or more of the following co\-morbidities:, uncontrolled systemic
  • hypertension (\>140/90
  • mmHg) , renal failure (eGFR \<30\), recent diagnosis of pulmonary
  • embolism (within 6 months).
  • \- Contraindication for CMR imaging:

Outcomes

Primary Outcomes

Not specified

Similar Trials